Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly.

Abstract

OBJECTIVE:

To evaluate GH and IGF-I control and tumour shrinkage in newly diagnosed patients with acromegaly treated first-line with lanreotide-Autogel (ATG) 120 mg. Design Open, prospective.

PATIENTS:

Twenty-six patients (17 women, aged 31-70 years): eight enclosed and 12 extrasellar (eight invasive) macroadenomas and six microadenomas (one invasive). ATG 120 mg initially given every 4 weeks for 12 weeks; then intervals between injections increased to every 6 or 8 weeks if GH levels were <or= 2.5 or < 1 microg/l (equal to 6.5 and 2.6 mU/l), respectively.

RESULTS:

Final dosage was ATG 120 mg every 4 weeks in nine patients (34.6%), every 6 weeks in eight patients (30.8%) and every 8 weeks in the remaining nine patients (34.6%). After 12 months, both GH and IGF-I were controlled in 14 patients (53.8%). The mean tumour volume decreased from 1405 +/- 1827 mm(3) at study entry to 960 +/- 1381 mm(3) after 6 months, and 799 +/- 1161 mm(3) after 12 months (P < 0.0001). Overall tumour shrinkage was 35.8 +/- 28.1% after 6 months and 48.4 +/- 27.6% after 12 months. After 12 months, 20 patients (76.9%) achieved > 25% tumour shrinkage: 12 of 14 with controlled disease (85.7%) and 8 of 12 with noncontrolled disease (66.7%; P = 0.49). Hyperhydrosis, paresthesiae and arthralgias significantly reduced after treatment. No patient withdrew from the study because of adverse events.

CONCLUSION:

ATG 120 mg in newly diagnosed patients with acromegaly controls GH and IGF-I secretion in 53.8% and induces >or= 25% tumour shrinkage in 76.9% during a 12-month period. The treatment was associated with improvement of clinical symptoms and with a good safety profile.

• Authors: Annamaria Colao, Renata S Auriemma, Alberto Rebora, Mariano Galdiero, Eugenia Resmini, Francesco Minuto, Gaetano Lombardi, Rosario Pivonello, Diego Ferone
• Journal: Clinical endocrinology (Clin Endocrinol (Oxf)) Vol. 71 Issue 2 Pg. 237-45 (Aug 2009) ISSN: 1365-2265 [Electronic] England
• PMID: 19094074 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Peptides, Cyclic
• lanreotide
• Human Growth Hormone
• Somatostatin
• Insulin-Like Growth Factor I

Topics

• Acromegaly (drug therapy, metabolism, pathology)
• Adenoma (drug therapy, metabolism, pathology)
• Adult
• Aged
• Antineoplastic Agents (administration & dosage)
• Dose-Response Relationship, Drug
• Female
• Human Growth Hormone (metabolism)
• Humans
• Insulin-Like Growth Factor I (metabolism)
• Male
• Middle Aged
• Peptides, Cyclic (administration & dosage)
• Prospective Studies
• Somatostatin (administration & dosage, analogs & derivatives)
• Treatment Outcome
• Tumor Burden (drug effects)